Panakeia Technologies

Panakeia is the world’s first in silico multi-omics company, building AI solutions to uncover complete biology at scale and accelerate precision medicine research, drug discovery, development and clinical decision-making.

Panakeia’s PANProfiler platform uses a biology-first AI approach to determine biomarker status across DNA, RNA, proteins and metabolites, directly from routinely used brightfield images of cells and tissues. The PANProfiler platform has been independently validated in peer-reviewed publications, including Communications Medicine, where the work was recognised as one of the journal’s top 25 papers of 2024. Two UKCA-marked clinical products derived from the platform are deployed in hospitals, enabling faster and more accessible precision diagnostics.

Panakeia’s AI platform for in silico multi-omics uncovers complete biological blueprints at scale for precision medicine in drug discovery and clinical decision-making:

• Multi-omics approaches unlock new insights across research, drug discovery and development, and the clinic
• Solving the biggest problems in drug discovery: reducing drug failure rates and improving patient outcomes
• True multi-omics insights remain elusive — held back by missing data, long turnaround times, and high costs
• Panakeia’s in silico multi-omics approach is enabled by a powerful, biology-first AI platform, developed by a multi-disciplinary team with deep expertise in multi-omics and AI multimodal foundation models
• The PANProfiler platform can accurately determine biomarkers across all building blocks of life (DNA, RNA, protein, metabolites) from routinely used brightfield images of cells and tissues
• Strong validation to date, with the platform technology published in Communications Medicine (one of the journal’s top 25 papers of 2024)
• Two UKCA-marked products derived from the PANProfiler platform (PANProfiler Breast and Colorectal), deployed in hospitals
• Creating a new frontier in our understanding of biology for drug development and healthcare with AI

Panakeia’s technology uncovers biological blueprints and understands physiological states at every level:

• The patent-pending PANProfiler platform employs a biology-first approach to unlocking the central dogma of biology at scale
• Uncovering new biology through powerful foundation models trained on petabytes of population-scale data, incorporating proprietary biological insights
• Actionable outputs including genomic, epigenomic, transcriptomic, proteomic, and metabolomic data
• Integrates with existing workflows and is easy to use without specialist training

The PANProfiler platform is trusted by research, pharmaceutical and healthcare organisations worldwide:

• Access to population-scale, functional -omics data through strategic partnerships
• Enabling novel target discovery and clinical trial success for key biopharma partners
• Two clinical products deployed across several clinical sites in the UK, India and the US
• Global delivery at scale through strategic channel partnerships
• Ethical, safe, patient-first platform setting the gold standard in healthcare AI:
• Establishing regulations for safe, accelerated access to AI, working with the MHRA (as part of the MHRA Airlock programme) and the FDA (through the DigiPath project, Friends of Cancer Research)
• Certifications and compliance include ISO 13485, ISO 27001, Cyber Essentials, GDPR, SOC 2 and HIPAA
• Proven accuracy and reproducibility, validated in the largest clinical study of its kind on more than 4,000 samples, with results presented at leading scientific conferences (incl.ESMO, ASCO, AACR) and in peer-reviewed journals (incl.Nature)
• Thought leaders in AI, contributing to policy and participating in industry-wide consortia

Multi-disciplinary team with deep expertise at the intersection of AI, biology and commercialising novel technologies:

• Patient-driven at the core, and founded on first-hand experience with the shortfalls of current cancer care pathways
• Leadership team with strong experience commercialising highly innovative technologies
• Deep technical expertise across disciplines including molecular biology, computational biology and AI
• Diverse backgrounds ensure a well-rounded approach to commercialisation, driven by customer and patient needs
• Advisors and board include world-leading experts in AI, drug development and precision medicine
• A global syndicate of investors: Ascension, Duke Capital Partners, LocalGlobe, Macmillan Innovation
• Impact Investments, Hoxton Ventures, Entrepreneur First, Leading industry experts